Q-omics provides the consensus-scored BMP3 profile across patient tissues and cancer cell-line models. BMP3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BMP3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, BMP3 RNA expression shows 13,372 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where BMP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMP3 survival associations across molecular data types. BMP3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMP3 RNA expression–survival associations across cancer types. High BMP3 expression shows unfavorable associations in KICH and STAD, but favorable associations in CHOL, KIRC, HNSC and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for BMP3 RNA expression.
This table summarizes BMP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BMP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMP3 shows lower tumor expression in COAD, LUSC, HNSC, KIRC, READ and STAD. The COAD box plot shows higher BMP3 RNA expression in normal versus tumor tissue (log2 FC = −4.399, t-test p < 0.001).
This table shows molecular features associated with BMP3 in patient tissues and cancer cell lines. In patient samples, BMP3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BMP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUSC.
